Search

Background: Adolescent solid organ transplant recipients (aSOTRs) who received three doses of the COVID‐19 mRNA vaccine experience high seroconversion rates and antibody persistence for up to 3 months. Long‐term antibody durability beyond this timeframe following three doses of the SARS‐CoV‐2 mRNA vaccine remains unknown. We describe antibody responses 6 months following the third vaccine dose (D3) of the BNT162b2 mRNA vaccination among aSOTRs. Methods: Participants in a multi‐center, observational cohort who received the third dose of the vaccine were analyzed for antibodies to the SARS‐CoV‐2 spike protein receptor‐binding domain (Roche Elecsys anti‐SARS‐CoV‐2‐S positive: ≥0.8, maximum: >2500 U/mL). Samples were collected at 1‐, 3‐, and 6‐months post‐D3. Participants were surveyed at each timepoint and at 12‐months post‐D3. Results: All 34 participants had positive anti‐RBD antibody titers 6 months post‐D3. Variations in titers occurred between 3 and 6 months post‐D3, with 8/28 (29%) having decreased antibody levels at 6 months compared to 3 months and 2/28 (7%) reporting increased titers at 6 months. The remaining 18/28 (64%) had unchanged antibody titers compared to 3‐month post‐D3 levels. A total of 4/34 (12%) reported breakthrough infection within 6 months and 3/32 (9%) reported infection after 6–12 months following the third dose of the SARS‐CoV‐2 mRNA vaccine. Conclusions: The results suggest that antibody durability persists up to 6 months following three doses of the SARS‐CoV‐2 mRNA in aSOTRs. Demography and transplant characteristics did not differ for those who experienced antibody weaning. Breakthrough infections did occur, reflecting immune‐evasive nature of novel variants such as Omicron. [ABSTRACT FROM AUTHOR]

Background: There has not been a comprehensive global survey of pediatric‐deceased donor allocation practices across all organs since the advent of deceased donor transplantation at the end of the 20th century. As an international community that is responsible for transplanting children, we set out to survey the existing landscape of allocation. We aimed to summarize current practices and provide a snapshot overview of deceased donor allocation practices to children across the world. Methods: The International Registry in Organ Donation and Transplantation (IRODAT, www.irodat.org) was utilized to generate a list of all countries in the world, divided by continent, that performed transplantation. We reviewed the published literature, published allocation policy, individual website references and associated links to publicly available listed allocation policies. Following this, we utilized tools of communication, relationships, and international fellowship to confirm deceased donation pediatric centers and survey pediatric allocation practices for liver, kidney, heart, and lung across the world. We summarize pediatric allocation practices by organ when available using source documents, and personal communication when no source documents were available. Results: The majority of countries had either formal or informal policies directed toward minimizing organ distribution disparity among pediatric patients. Conclusion: Children have long‐term life to gain from organ donation yet continue to die while awaiting transplantation. We summarize global strategies that have been employed to provide meaningful and sustained benefit to children on the waitlist. [ABSTRACT FROM AUTHOR]

Background: The number of programs offering a PTH fellowship has grown rapidly over the last 10 years. This study aimed to describe the clinical, didactic, procedural, and research experiences of recent PTH fellowship graduates. In addition, we sought to understand graduates' post‐fellowship professional responsibilities and their perception about the utility of the PTH fellowship. Methods: An anonymous survey was distributed from February to October 2020 through REDCap to all recent graduates (2015–2019) of an ACGME‐approved PTH fellowship program. The survey consisted of 49 questions focused on the PTH fellowship experience. Results were summarized using descriptive statistics. Results: Thirty‐eight of 43 graduates (88%) responded to the survey representing 12 PTH fellowship programs. The didactic experience varied; 97% received pathology lectures, 81% radiology lectures, 54% organ allocation lectures, 54% procedural lectures, 57% immunology lectures, and 43% live donation lectures. During the PTH fellowship, the majority of fellows performed >10 liver biopsies (82%) and >5 variceal bandings (58%); however, 63%, 32%, 8%, and 8% never performed paracentesis, variceal sclerotherapy, variceal banding, and liver biopsies, respectively. The majority of fellows (95%) completed a research project during PTH fellowship. Currently, 84% of graduates are employed at a transplant academic institution. All graduates recommended the fellowship. Conclusions: There is variability in the didactic, clinical, and procedural training among PTH fellowship programs. Although uniformly viewed as a beneficial fellowship year, there is an opportunity to collaborate to create a more standardized training experience. [ABSTRACT FROM AUTHOR]

The demand for kidney transplant is quite high compared with the current supply, even with the increasing numbers of transplant deceased donors since 2019.6 Pediatric kidney-alone and multiple organ transplant candidates compete for the same high-quality donor kidneys, but under the current OPTN allocation policy multiple organ transplants have ultimate priority. During the study period, children receiving kidney-alone transplants had the highest one-year graft survival (98.2%) compared with K-P (96.6%) and other multiple organ transplants (87.9%-88.2%). Although the OPTN/UNOS has a well-defined history of giving priority to children, it has not yet begun to address in policy the multiple organ transplant effect on pediatric priority due to the perceived complexity of multiple organ allocation. [Extracted from the article]

Machine learning analyses allow for the consideration of numerous variables in order to accommodate complex relationships that would not otherwise be apparent in traditional statistical methods to better classify patient risk. The SPLIT registry data were analyzed to determine whether baseline demographic factors and clinical/biochemical factors in the first‐year post–transplant could predict ideal outcome at 3 years (IO‐3) after LT. Participants who received their first, isolated LT between 2002 and 2006 and had follow‐up data 3 years post–LT were included. IO‐3 was defined as alive at 3 years, normal ALT (<50) or GGT (<50), normal GFR, no non‐liver transplants, no cytopenias, and no PTLD. Heat map analysis and RFA were used to characterize the impact of baseline and 1‐year factors on IO‐3. 887/1482 SPLIT participants met inclusion criteria; 334 had IO‐3. Demographic, biochemical, and clinical variables did not elucidate a visual signal on heat map analysis. RFA identified non‐white race (vs white race), increased length of operation, vascular and biliary complications within 30 days, and duct‐to‐duct biliary anastomosis to be negatively associated with IO‐3. UNOS regions 2 and 5 were also identified as important factors. RFA had an accuracy rate of 0.71 (95% CI: 0.68‐0.74), PPV = 0.83, and NPV = 0.70. RFA identified participant variables that predicted IO‐3. These findings may allow for better risk stratification and personalization of care following pediatric liver transplantation. [ABSTRACT FROM AUTHOR]